Acrux Limited ACR
ASX · Australia · Health Technology
AUD 0.0100+0.00 (+11.11%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Acrux is a successful Australian pharmaceutical company that develops innovative drugs for the global market. It recently announced its new strategy to enter the final, phase III clinical trial, stage of development for a Female Testosterone product. This continues the company's heritage in designing and developing patient-preferred drug delivery systems and it address a large unmet patient need. The unmet need is Hypoactive Sexual Desire Disorder (HSDD) or, in common English low libido or low s
The Australian market has recently experienced a mixed performance, with materials dragging down the indices while energy stocks showed resilience amid shifting global economic sentiments. In this context, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment of interests, making them worth considering in today's fluctuating market environment.
As the Australian market continues to navigate a mix of economic signals, with the ASX 200 climbing past the 9,000 mark amidst speculation of potential rate cuts and strong sector performances, investors are keenly observing opportunities that align with these shifting dynamics. In this context, growth companies with high insider ownership can be particularly appealing as they often indicate confidence from those most familiar with their operations and potential for long-term success.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.